
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
MUNICH - Dermatologists now have a clinical case that supports the loss of heterozygosity theory for rare Type 2 form of segmental types of autosomal dominant (AD) skin disorders, Peter Itin, M.D., said at the annual meeting of the European Academy of Dermatology and Venereology.






